Foster & Motley Inc. Increases Stock Holdings in Pacira BioSciences, Inc. $PCRX

Foster & Motley Inc. lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 172.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 41,057 shares of the company’s stock after acquiring an additional 25,984 shares during the period. Foster & Motley Inc.’s holdings in Pacira BioSciences were worth $1,063,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Doma Perpetual Capital Management LLC increased its holdings in Pacira BioSciences by 49.7% during the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company’s stock valued at $69,613,000 after acquiring an additional 897,255 shares in the last quarter. Balyasny Asset Management L.P. lifted its holdings in shares of Pacira BioSciences by 36.1% in the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock valued at $50,925,000 after purchasing an additional 565,288 shares in the last quarter. EcoR1 Capital LLC purchased a new stake in shares of Pacira BioSciences in the second quarter valued at about $10,934,000. Goldman Sachs Group Inc. grew its position in shares of Pacira BioSciences by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after purchasing an additional 367,869 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of Pacira BioSciences by 87.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,143 shares of the company’s stock valued at $11,262,000 after purchasing an additional 202,773 shares during the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Stock Performance

NASDAQ PCRX opened at $22.79 on Thursday. The business’s 50-day moving average price is $22.07 and its 200 day moving average price is $23.29. The company has a current ratio of 4.54, a quick ratio of 3.28 and a debt-to-equity ratio of 0.54. Pacira BioSciences, Inc. has a twelve month low of $18.80 and a twelve month high of $27.64. The company has a market capitalization of $922.77 million, a PE ratio of 151.93 and a beta of 0.21.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). The company had revenue of $196.87 million for the quarter, compared to analyst estimates of $201.93 million. Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.91 EPS. On average, research analysts predict that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on PCRX shares. Weiss Ratings restated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Pacira BioSciences in a report on Friday, January 9th. Zacks Research downgraded Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research report on Monday, March 9th. Barclays cut their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. Finally, Wall Street Zen downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $30.25.

Insider Buying and Selling

In other Pacira BioSciences news, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the transaction, the senior vice president owned 52,313 shares in the company, valued at $1,088,633.53. This trade represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jonathan Slonin sold 3,261 shares of Pacira BioSciences stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total transaction of $74,416.02. Following the completion of the transaction, the insider owned 223,640 shares in the company, valued at approximately $5,103,464.80. This trade represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 8,677 shares of company stock valued at $191,980. 6.40% of the stock is owned by insiders.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.